科研动态PubMed 摘要

IgG4ward!基金会关于IgG4相关性疾病治疗的指南。

PubMed 白名单日捞 · 2026-11-09

完整摘要 · 中文译文

IgG4相关性疾病是一种慢性、免疫介导的全身性疾病,表现为肿瘤样肿块。自2015年发布上一版关于IgG4相关性疾病治疗的国际共识声明以来,相关文献量大幅增加,过去2年内发表了两项3期随机安慰剂对照试验。这一治疗决策的证据基础使得制定新的专门治疗指南成为必要。来自六大洲15个国家的62名研究者——包括52名医生、一名医学参考馆员、8名患者和一名照护者——被召集组成治疗指南小组。这些医生涵盖广泛的专业领域,患者代表性覆盖了全部器官受累谱系。治疗指南小组提出了183个候选问题,经IgG4ward!顾问委员会批准后整合为40个最终问题。这些问题构成了由一名医学参考馆员主导的系统性文献检索的基础,该检索为28条治疗声明的制定提供了依据。每条声明的支持证据均使用2011年牛津循证医学中心证据水平框架独立分级。52名医生对每条声明的同意程度进行了电子投票;共识要求超过80%的医生同意或强烈同意该声明,28条声明中有22条达成了共识。由于3期临床试验的发表,证据基础反映了近期显著进展,尽管大多数声明…… 仍依赖于低级别证据。这项工作由来自不同地域和专业领域的IgG4相关性疾病专家组成的小组提供了连贯的、基于共识的指南,反映了自2015年以来该领域的演变。尽管取得了这些进展,重要的知识空白仍然存在,并被突出强调以指导未来的研究。

完整摘要 · 英文原文

IgG4-related disease is a chronic, immune-mediated, systemic condition that presents as tumour-like masses. Since publication of the last international consensus statement on the treatment of IgG4-related disease in 2015, the related literature has expanded considerably, with two phase 3, randomised, placebo-controlled trials published within the past 2 years. This foundation of evidence for treatment decisions justified new, dedicated treatment guidelines. 62 investigators-comprising 52 physicians, one medical reference librarian, eight patients, and one caregiver from 15 countries across six continents-were assembled to form a treatment guidelines group. The physicians had a broad range of specialties and patient representation spanned the full spectrum of organ involvement. The treatment guidelines group generated 183 candidate questions, which were consolidated into 40 final questions approved by the IgG4ward! Advisory Board. These questions formed the basis of a systematic literature search, led by a medical reference librarian, which informed the development of 28 treatment statements. Supporting evidence for each statement was independently graded using the 2011 Oxford Centre for Evidence-Based Medicine Levels of Evidence framework. The 52 physicians voted electronically on their level of agreement with each statement; consensus required more than 80% to agree or strongly agree with the statement, and was reached for 22 of the 28 statements. The evidence base reflects marked recent progress due to the publication of phase 3 clinical trials, although most statements still rely on low-level evidence. This effort provides cohesive, consensus-based guidelines from a geographically and professionally diverse group of experts in IgG4-related disease, reflecting the evolution in the field since 2015. Despite this progress, important knowledge gaps remain, and are highlighted to guide future research.

English
The IgG4ward! Foundation guidelines on the treatment of IgG4-related disease.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界